The rising frequency of Parkinson's disease and epilepsy is predicted to drive up demand for DBS devices. Major market players are focusing on the approval and introduction of new DBS devices to extend their product portfolio, and key market players are focusing on the market launch of updated versions of their previously authorised DBS devices, which is projected to promote market growth. One of the major reasons impeding the growth of the global deep brain stimulation device market is the related hazards connected with deep brain stimulation operations such as lead misplacement and brain haemorrhage. The implanted pulse generator, for example, is the primary power source and programmable component of DBS devices (IPG). The use of deep brain stimulation devices for Parkinson's disease is expected to be limited because to the risk of infection caused by IPG. As a result, healthcare stakeholders should educate patients on the usage of tack-up sutures and low-profile devices, as well as antimicrobial impregnation and co-administration.
According to Coherent Market Insights, Global Deep Brain Stimulation Device Market size was valued at US$ 1,188.9 million in 2022 and is expected to witness a CAGR of 9.8% over the forecast period (2022 – 2030).
Key Leaders in the Deep Brain Stimualtion Industry:
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Medtronic, Inc.
Medtronic Navigation, Inc. provides integrated navigation and intra-operative imaging solutions. The company was founded in 1995, headquartered in Colorado, U.S.
St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological
